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that harnesses X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy and is not only considered a breakthrough in computational chemistry but also has accelerated in silico screening of chemical compound libraries. The technique is a faster and less expensive alternative to the traditional high-throughput screening methods. We previously screened various inhibitors of mycobacterial enzymes (e.g., enoyl-acyl carrier protein reductase [16] [17] [18] and thymidine monophosphate kinase [19] ) using in silico SBDS and experimentally confirmed the antimycobacterial activity of the screened compounds. The high-resolution crystal structure of M. tuberculosis CmaA1 has been previously published; therefore, in this study, we attempted to identify compounds that were capable of interacting with the mycobacterial CmaA1 active site by combing through a considerably large virtual compound library using in silico SBDS with an intent to examine the antimycobacterial activity of the selected compounds.
MaterIals and Methods

Analysis of the compound library and protein structural data
The 3D virtual chemical library, comprising 461,383 compounds and supplied by ChemBridge (San Diego, CA, USA), was derived from the Ressource Parisienne en Bioinformatique Structurale (Paris, France) web-based database, as previously described. [16] 2D structures of the compounds were converted to 3D structures using the stereochemistry module of the Molecular Operating Environment (MOE; Chemical Computing Group, Montreal, Canada) application. Protonation states were adjusted at pH 7.0, and multiple conformations of the compounds were generated using the Protonate 3D module and conformation search module in MOE. The 3D structural data of M. tuberculosis CmaA1 complexed with S-adenosyl-L-homocysteine and didecyldimethylammonium (PDB-id 1KPH; resolution, 2.0 Å) [20] was used for the present in silico SBDS. Hydrogen atoms were assigned to the structural data using the DOCK Prep tool. The molecular surface of the structure was calculated using the DMS program, and the docking pocket for drug screening (i.e., active site cavity of the enzyme) was determined using the SPHGEN program. [21] In silico structure-based drug screening
The three-step in silico SBDS was performed using a combination of two applications-UCSF DOCK ( v e r s i o n 6 . 3 ) [22] a n d G O L D , [23, 24] a s p r e v i o u s l y described. [16] [17] [18] [19] 25] In brief, the top 3,000 compounds with a DOCK score of <−55 kcal/mol were selected by screening the library using the DOCK program; this was designated as primary screening. Next, the selected compounds were screened using the GOLD program, which constituted the secondary screening. Ten multiple conformations of the compounds with a high GOLD score were generated using the LowModeMD in MOE and were then rescreened with the GOLD program; this comprised the tertiary screening. Structurally related compounds among the active compounds obtained prior to SBDS were targeted within a chemical library that comprised approximately 1,000,000 compounds (ChemBridge). Ten multiple conformations of compounds with a high Tanimoto coefficient (>0.85 for compound 1; >0.65 for compound 5) were generated, as described earlier, after which the docking simulation was performed using the GOLD program.
Candidate compounds
The candidate compounds identified via SBDS were purchased from ChemBridge. The NMR and/or liquid chromatography/ mass spectrometry data related to the compounds are available on the manufacture's website at http://www.chembridge. com. Hereafter, the series of the screened compounds were designated as follows: 1-10, 1a-1e, and 5a-5e [ Tables 1 and 2 ]. 
results
Structure-based drug screening of Mycobacterium tuberculosis cyclopropane mycolic acid synthase 1 inhibitor
In this study, in silico SBDS of the 461,383-compound library was performed to identify CmaA1-targeted novel antibiotics for M. tuberculosis. The van der Waals molecular surface of the drug-binding cavity in M. tuberculosis CmaA1 (1KPH) is shown in Figure 1 . The three-step screening strategy using the DOCK and GOLD applications has been previously described. [16, 17, 19, 25] The primary DOCK screening identified the top 3,000 ranked chemical compounds with a DOCK score of <−55 kcal/mol. The subsequent GOLD screenings (secondary screening: Single conformation; tertiary screening: Multiple conformations) led to the identification of 10 compounds (1-10) with high GOLD scores. The IUPAC names, molecular weights, and GOLD scores of the candidate compounds are summarized in Table 1 , and their chemical structures are represented in Figure S1 .
Antimycobacterial growth assessment of the selected compounds via structure-based drug screening
Antimycobacterial activity of the 10 candidate compounds was measured to evaluate their inhibitory effect on mycobacterial growth. Nonpathogenic M. smegmatis (biosafety level 1) was used as a model Mycobacterium considering its similarity of primary structures with those of M. tuberculosis; the similarity of M. smegmatis CmaA1 to M. tuberculosis CmaA1 is sufficient (80% similar). Figure 2 shows the inhibitory effects of the candidate compounds on the growth of M. smegmatis. Compounds 1 and 5 exhibited strong inhibition, and compounds 6 and 10 showed moderate inhibition. Dose dependence of the inhibitory effect of compounds 1 and 5 was further examined [ Figure 3 ]. IC 50 values, concentration at which 50% of M. smegmatis growth is inhibited, of compounds 1 and 5 were 5.1 and 31 µM, respectively.
In silico screening of the structurally related compounds 1 and 5
Among the candidate compounds, 1 and 5 showed remarkable inhibitory effect on M. smegmatis growth. To further study the association between their structure and activity, structurally related compounds, that is, 1a-1e for compound 1 and 5a-5e for compound 5, were identified within the chemical library, as previously described. [17, 18, 25] The IUPAC names, molecular weights, GOLD scores, and chemical structures of the compounds are summarized in Table 2 and Figure 4 . As shown in Figure 5 , compounds 1c and 1e exhibited a significant inhibitory effect on M. smegmatis growth, whereas the inhibitory effect of compound 5-related composites was undetectable. The IC 50 values of the compounds 1c and 1e were 45.6 µM, 5.6 µM, respectively [ Figure 5 ].
dIscussIon
The in silico SBDS approach has been used to identify novel chemicals from virtual compound libraries with widely used docking simulation tools. The DOCK-GOLD tandem screening employed in this study resulted in the identification of two compounds with antimycobacterial activity (compounds 1 and 5), and the following GOLD screening based on the structural similarity of compounds 1 and 5 identified two more active compounds (compounds 1c and 1e). Among the four compounds, the IC 50 value of 1 (5.1 µM) and 1e (5.6 µM) was comparable to that of isoniazid (5.4 µM). The in silico screening used in this study identified two promising compounds among the experimentally validated 20 compounds (hit rate, 10%), despite the hit rate of random high-throughput screening approaches generally being 1%-3%. Therefore, a combination of the DOCK-GOLD tandem in silico SBDS and successive screening for structural similarity may help in cost and labor savings in general drug screening.
The protein-ligand interaction fingerprint and the ligand interaction in MOE predicted the putative interaction of compounds 1, 5, 1c, and 1e with Phe 200 , Arg 204 , and Leu 205 of CmaA1, which involves a binding loop (residues 199-207) for α-mycolate acyl group. [26] According to our preliminary experiments, the aforementioned active compounds (1, 5, 1c, and 1e) did not inhibit the activity of the representative Gram-negative bacteria, Escherichia coli BL21 strain [ Figure S2 ]; we should also mention that CmaA1 has not been identified in E. coli.
Elucidation of further antibacterial mechanisms of the candidate compounds such as target-enzyme specificity, biophysical binding properties, including co-crystal structure, and effect on enzyme kinetics and inhibiting mechanism remain to be studied in the future. Nonetheless, irrespective of the evident experimental insufficiency, we believe that an accumulation of knowledge on pharmacophores related to mycobacterial growth inhibition would be valuable for the development of novel anti-TB drugs. The structural features of compounds 1, 1c, and 1e, including the nitric groups on 1,3-dioxo-isoindol and the central amide bond, constitute structural requirements for exerting their potent antimycobacterial activity. In addition, the 4-methyl-2-oxo-chromen group of compound 5 is structurally unique among the tested compounds, suggesting that the group is important in the compound's antimycobacterial action.
conclusIon
In the present study, we achieved to identify two compounds (compounds 1 and 1e) with potent inhibitory effects on mycobacterial growth. These compounds identified via present SBDS were expected to be a novel class of antituberculosis pharmacophores and the SBDS techniques are expected as powerful tool for antimycobacterial drug screening. 
